EGFR and cancer: Currently, there are many mAbs available on the market that target different cancers, such as Trastuzumab, Pertuzumab, and Margetuximab for HER2+ cancers (25), Rituximab for non-Hodgkin’s lymphoma (26), and Cetuximab for EGFR+ colorectal cancer (27).